Latest news with #Telomir-1
Miami Herald
3 days ago
- Health
- Miami Herald
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, FL / ACCESS Newswire / June 5, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company," an emerging leader in age-reversal science, today announced compelling new preclinical data demonstrating that its lead candidate, Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS)-a rare genetic disorder also known as adult-onset progeria. These findings confirm and build upon the Company's previously reported results from a preclinical C. elegans study, which demonstrated that Telomir-1 restored lifespan and normalized physiological decline in animals with a wrn gene mutation. Werner Syndrome: A Rare and Devastating Accelerated Aging Disorder Werner Syndrome is a rare autosomal recessive disorder caused by mutations in the wrn gene, which plays a critical role in DNA repair and telomere maintenance. Patients typically begin showing signs of premature aging-such as graying hair, cataracts, diabetes, osteoporosis, and atherosclerosis-in their 20s or 30s. Median life expectancy is 40-50 years. There are currently no FDA-approved treatments. To model this disease, the Company's study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which replicates key features of Werner Syndrome, including telomere loss, mitochondrial dysfunction, retinal degeneration, muscle deterioration, and abnormal DNA methylation. Key Preclinical Findings 1. DNA Methylation Reversal - Resetting the Genetic ClockDNA methylation is one of the body's key mechanisms for controlling which genes are turned on or off. It works by attaching small chemical tags (called methyl groups) to DNA at locations known as CpG islands-which act like gene "on/off" switches. When methylation patterns are intact, cells know which genes to express and when. However, with aging and disease, this regulatory system starts to break down - a phenomenon known as epigenetic drift. In these cases, genes that should be off may turn on inappropriately, and protective genes may be silenced. This malfunction in gene regulation is strongly linked to a wide range of chronic diseases including: Cancer (via silencing of tumor suppressor genes)Neurodegenerative diseases like Alzheimer's and Parkinson'sAutoimmune diseases such as lupus and multiple sclerosisMetabolic conditions like Type 2 diabetesPremature aging disorders like progeria and Werner Syndrome In this study, Telomir-1 reversed age-related hypomethylation at two chromosomal regions, restoring methylation patterns to above-normal wild-type levels. This suggests that Telomir-1 may help restore healthy gene regulation and reset the body's epigenetic aging clock, reducing the risk of dysfunction in key biological systems. 2. Telomere Elongation - Rebuilding the Chromosomal ClockTelomeres are the protective caps at the ends of chromosomes that shorten with each cell division and under stress. Telomere shortening is considered one of the hallmarks of aging. In the study, compared with the shortened length in the mutated animals, Telomir-1 increased telomere length by about three-fold. At the higher dose, telomere length significantly exceeded wild-type (healthy) levels, suggesting not only restoration but also potential enhancement of chromosomal integrity 3. Muscle Mass and Body Weight RecoveryIn the wrn-mutant zebrafish model, animals exhibited a 50-60% reduction in body weight and muscle volume. After 14 days of Telomir-1 treatment, these physical markers were restored to levels statistically indistinguishable from healthy controls - indicating functional recovery and metabolic improvement. 4. Oxidative Stress ReductionReactive oxygen species (ROS), which damage cells and accelerate aging, were elevated in untreated animals. Telomir-1 reduced ROS levels by up to 50%, suggesting improved cellular resilience. 5. Survival BenefitRoughly 15% of untreated animals died during the 14-day study period, whereas no deaths occurred in any Telomir-1 treated groups - highlighting a systemic survival advantage. "These results reinforce my conviction that Telomir-1 may represent one of the most important scientific developments in the field of aging," said Erez Aminov, Chairman and CEO of Telomir. "While we remain in the preclinical phase, the consistency and strength of the data demand serious attention. My full commitment is behind advancing Telomir-1 toward human studies in the most responsible and rigorous way. The potential here is too significant to ignore." "This is one of the most comprehensive rejuvenation profiles we've seen in a vertebrate aging model," added Dr. Itzchak Angel, Chief Scientific Advisor. "The ability to reverse both genomic and epigenetic instability while improving survival supports the growing potential of Telomir-1 as a foundational therapy for aging-related diseases." Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information Helga Moya info@ 396-6723 SOURCE: Telomir Pharmaceuticals, Inc
Indianapolis Star
3 days ago
- Business
- Indianapolis Star
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival – highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, FL / ACCESS Newswire Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the 'Company,' an emerging leader in age-reversal science, today announced compelling new preclinical data demonstrating that its lead candidate, Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS) -a rare genetic disorder also known as adult-onset progeria. These findings confirm and build upon the Company's previously reported results from a preclinical C. elegans study, which demonstrated that Telomir-1 restored lifespan and normalized physiological decline in animals with a wrn gene mutation. Werner Syndrome: A Rare and Devastating Accelerated Aging Disorder Werner Syndrome is a rare autosomal recessive disorder caused by mutations in the wrn gene, which plays a critical role in DNA repair and telomere maintenance. Patients typically begin showing signs of premature aging-such as graying hair, cataracts, diabetes, osteoporosis, and atherosclerosis-in their 20s or 30s. Median life expectancy is 40-50 years. There are currently no FDA-approved treatments. To model this disease, the Company's study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which replicates key features of Werner Syndrome, including telomere loss, mitochondrial dysfunction, retinal degeneration, muscle deterioration, and abnormal DNA methylation. Key Preclinical Findings 1. DNA Methylation Reversal – Resetting the Genetic Clock DNA methylation is one of the body's key mechanisms for controlling which genes are turned on or off. It works by attaching small chemical tags (called methyl groups) to DNA at locations known as CpG islands -which act like gene 'on/off' switches. When methylation patterns are intact, cells know which genes to express and when. However, with aging and disease, this regulatory system starts to break down – a phenomenon known as epigenetic drift. In these cases, genes that should be off may turn on inappropriately, and protective genes may be silenced. This malfunction in gene regulation is strongly linked to a wide range of chronic diseases including: Cancer (via silencing of tumor suppressor genes) Neurodegenerative diseases like Alzheimer's and Parkinson's Autoimmune diseases such as lupus and multiple sclerosis Metabolic conditions like Type 2 diabetes Premature aging disorders like progeria and Werner Syndrome In this study, Telomir-1 reversed age-related hypomethylation at two chromosomal regions, restoring methylation patterns to above-normal wild-type levels. This suggests that Telomir-1 may help restore healthy gene regulation and reset the body's epigenetic aging clock, reducing the risk of dysfunction in key biological systems. 2. Telomere Elongation – Rebuilding the Chromosomal Clock Telomeres are the protective caps at the ends of chromosomes that shorten with each cell division and under stress. Telomere shortening is considered one of the hallmarks of aging. In the study, compared with the shortened length in the mutated animals, Telomir-1 increased telomere length by about three-fold. At the higher dose, telomere length significantly exceeded wild-type (healthy) levels, suggesting not only restoration but also potential enhancement of chromosomal integrity 3. Muscle Mass and Body Weight Recovery In the wrn-mutant zebrafish model, animals exhibited a 50-60% reduction in body weight and muscle volume. After 14 days of Telomir-1 treatment, these physical markers were restored to levels statistically indistinguishable from healthy controls – indicating functional recovery and metabolic improvement. 4. Oxidative Stress Reduction Reactive oxygen species (ROS), which damage cells and accelerate aging, were elevated in untreated animals. Telomir-1 reduced ROS levels by up to 50%, suggesting improved cellular resilience. 5. Survival Benefit Roughly 15% of untreated animals died during the 14-day study period, whereas no deaths occurred in any Telomir-1 treated groups – highlighting a systemic survival advantage. 'These results reinforce my conviction that Telomir-1 may represent one of the most important scientific developments in the field of aging,' said Erez Aminov, Chairman and CEO of Telomir. 'While we remain in the preclinical phase, the consistency and strength of the data demand serious attention. My full commitment is behind advancing Telomir-1 toward human studies in the most responsible and rigorous way. The potential here is too significant to ignore.' 'This is one of the most comprehensive rejuvenation profiles we've seen in a vertebrate aging model,' added Dr. Itzchak Angel, Chief Scientific Advisor. 'The ability to reverse both genomic and epigenetic instability while improving survival supports the growing potential of Telomir-1 as a foundational therapy for aging-related diseases.' Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information SOURCE: Telomir Pharmaceuticals, Inc View the original press release on ACCESS Newswire
Yahoo
3 days ago
- Business
- Yahoo
EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder
Telomir Pharmaceuticals Inc. (NASDAQ:TELO) on Thursday released new preclinical data for its lead candidate, Telomir-1. The data demonstrated that Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS)—a rare genetic disorder also known as adult-onset progeria. Adult progeria is a rare genetic disorder characterized by premature aging starting in late adolescence or early Syndrome is caused by mutations in the wrn gene, which plays a critical role in DNA repair and telomere maintenance. These findings confirm and build upon the company's previously reported results from a preclinical C. elegans study, which demonstrated that Telomir-1 restored lifespan and normalized physiological decline in animals with a wrn gene mutation. In this study, Telomir-1 reversed age-related hypomethylation at two chromosomal regions, restoring methylation patterns to above-normal wild-type levels. This suggests that Telomir-1 may help restore healthy gene regulation and reset the body's epigenetic aging clock, reducing the risk of dysfunction in key biological systems. Telomeres are the protective caps at the ends of chromosomes that shorten with each cell division and under stress. Telomere shortening is considered one of the hallmarks of aging. In the study, Telomir-1 increased telomere length by about three-fold compared to the shortened length in the mutated animals. At the higher dose, telomere length significantly exceeded wild-type (healthy) levels, suggesting restoration and potential enhancement of chromosomal integrity. In the wrn-mutant zebrafish model, animals exhibited a 50–60% reduction in body weight and muscle volume. After 14 days of Telomir-1 treatment, these physical markers were restored to levels statistically indistinguishable from healthy controls — indicating functional recovery and metabolic improvement. Reactive oxygen species (ROS), which damage cells and accelerate aging, were elevated in untreated animals. Telomir-1 reduced ROS levels by up to 50%, suggesting improved cellular resilience. Roughly 15% of untreated animals died during the 14-day study period, whereas no deaths occurred in any Telomir-1-treated groups. In March, Telomir Pharmaceuticals revealed preclinical findings demonstrating that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model with aggressive cancer cells. The company says that Telomir-1 actively suppresses cancer growth and protects against chemotherapy-induced toxicity and mortality when combined with Paclitaxel—a widely used chemotherapy but often associated with severe toxicity and side effects. Price Action: TELO stock closed at $2.11 on Wednesday. Read Next:Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
6 days ago
- Business
- Miami Herald
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026 MIAMI, FL / ACCESS Newswire / June 2, 2025 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced its participation in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has scheduled a full week of BIO One-on-One Partnering™ meetings to explore strategic collaborations, licensing opportunities, and potential M&A transactions. Telomir is actively preparing to submit an Investigational New Drug (IND) application by the end of this year for its lead candidate, Telomir-1-a novel small molecule designed to elongate telomeres, regenerate cells, and reverse core mechanisms of biological aging. The Company is gearing up for its pre-IND meeting with the FDA, with the goal of initiating first-in-human dosing in the first half of 2026. As part of its expanding pipeline, Telomir is advancing a rare-disease exploratory and developmental strategy focused on high-need orphan indications where cellular aging plays a central role. These include: Werner's syndrome, a rare adolescent- or adult-onset disorder often referred to as "adult Progeria," which is expressed by many features of premature aging, including early graying, cataracts, metabolic dysfunction, and cancer disease, a rare genetic disorder caused by copper accumulation in tissues. Telomir-1 has already demonstrated in preclinical testing copper-modulating capabilities, reversal of copper-induced toxicities and reactive oxygen species production, offering a potential disease-modifying approach that directly addresses the root cause of toxicity and inflammation associated with Wilson' an ultra-rare pediatric condition that causes rapid aging in children, where Telomir-1 has shown in animal models restoration of lifespan and normalization of disease including rare neuromuscular subtypes that impair vocal cord function and may be linked to inflammation and accelerated tissue degeneration. The Company plans to meet with the FDA to establish novel clinical endpoints across its rare disease programs, aiming to unlock accelerated development pathways and regulatory flexibility. In parallel, Telomir-1 is also being investigated in autism spectrum disorder, where its potential impact on telomere biology, oxidative stress, neurodegeneration and inflammation may offer a novel therapeutic approach for neurodevelopmental conditions. Beyond rare and neurological disorders, Telomir has achieved significant preclinical success across a range of high-impact therapeutic areas, underscoring the versatility of its platform: Vision Restoration: Structural and functional recovery of the retina in FDA-recognized endpoints in animal models of age-related macular degeneration (AMD).Longevity and Aging: Consistent age-reversal, increased lifespan, and improved health in standard aging, Werner's syndrome and in Progeria Disease: In preclinical models of Type 2 diabetes,Telomir-1 led to the reversal of elevated blood glucose, restoration of insulin sensitivity, improved pancreatic islet function, and a marked reduction in oxidative stress and systemic In a preclinical model of aggressive human prostate cancer, Telomir-1 alone at both low and high doses reduced tumor growth by approximately 50%, while also exhibiting a protective effect on healthy cells. These findings directly counter concerns that telomere-elongating drugs may promote cancer; instead, Telomir-1 actively suppressed tumor Disease: Development of Telomir-Ag2, a novel drug candidate with potent activity against multidrug-resistant bacteria, including MRSA. "The breadth of our preclinical data showcases the potential of Telomir-1 not just as a treatment-but as a platform for addressing aging-related and rare diseases at the source," said Erez Aminov, Chief Executive Officer of Telomir. "As we prepare for IND submission and for a pre-IND meeting with the FDA, we look forward to connecting with potential partners at BIO to explore licensing and M&A opportunities that can help accelerate our path to the clinic." Dr. Angel, Chief Scientific Advisor at Telomir, added:"In all my years in drug development, I've never seen a molecule with this kind of cross-indication potential. The science behind Telomir-1 is remarkable-it's addressing cellular aging at its root, and the preclinical data speak for themselves. What excites me most is how this one molecule may have the power to transform how we treat aging-related, metabolic, and rare genetic diseases across the board." Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information Helga Moya info@ 396-6723 SOURCE: Telomir Pharmaceuticals, Inc
Associated Press
6 days ago
- Business
- Associated Press
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026 MIAMI, FL / ACCESS Newswire / June 2, 2025 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ('Telomir' or the 'Company'), an emerging leader in age-reversal science, today announced its participation in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has scheduled a full week of BIO One-on-One Partnering™ meetings to explore strategic collaborations, licensing opportunities, and potential M&A transactions. Telomir is actively preparing to submit an Investigational New Drug (IND) application by the end of this year for its lead candidate, Telomir-1-a novel small molecule designed to elongate telomeres, regenerate cells, and reverse core mechanisms of biological aging. The Company is gearing up for its pre-IND meeting with the FDA, with the goal of initiating first-in-human dosing in the first half of 2026. As part of its expanding pipeline, Telomir is advancing a rare-disease exploratory and developmental strategy focused on high-need orphan indications where cellular aging plays a central role. These include: The Company plans to meet with the FDA to establish novel clinical endpoints across its rare disease programs, aiming to unlock accelerated development pathways and regulatory flexibility. In parallel, Telomir-1 is also being investigated in autism spectrum disorder, where its potential impact on telomere biology, oxidative stress, neurodegeneration and inflammation may offer a novel therapeutic approach for neurodevelopmental conditions. Beyond rare and neurological disorders, Telomir has achieved significant preclinical success across a range of high-impact therapeutic areas, underscoring the versatility of its platform: 'The breadth of our preclinical data showcases the potential of Telomir-1 not just as a treatment-but as a platform for addressing aging-related and rare diseases at the source,' said Erez Aminov, Chief Executive Officer of Telomir. 'As we prepare for IND submission and for a pre-IND meeting with the FDA, we look forward to connecting with potential partners at BIO to explore licensing and M&A opportunities that can help accelerate our path to the clinic.' Dr. Angel, Chief Scientific Advisor at Telomir, added: 'In all my years in drug development, I've never seen a molecule with this kind of cross-indication potential. The science behind Telomir-1 is remarkable-it's addressing cellular aging at its root, and the preclinical data speak for themselves. What excites me most is how this one molecule may have the power to transform how we treat aging-related, metabolic, and rare genetic diseases across the board.' Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information Helga Moya [email protected] (786) 396-6723 SOURCE: Telomir Pharmaceuticals, Inc press release
